SMI Adviser1.3.1
Publisher Description
SMI Adviser -App for person-centered care for individuals with serious mental illness (SMI).
Submit questions, access resources, and receive guidance from national experts in SMI.
Our mission is to advance the use of a person-centered approach to care that ensures people who have SMI find the treatment and support they need. For clinicians, we offer access to education, data, and consultations so you can make evidence-based treatment decisions. For individuals, families, friends, people who have questions, or people who care for someone with SMI, we offer access to resources and answers from a national network of experts. SMI Adviser is funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) and administered by the American Psychiatric Association (APA).
Funding for this initiative was made possible (in part) by Grant No. 1H79SM080818-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
*****
SMI Adviser is provided for general educational and informational purposes. It should not be construed as medical advice in connection with the care of a particular patient or as a statement of the standard of care. It is not necessarily inclusive of all potential treatments. The activities and materials offered through SMI Adviser should not be considered as providing the basis for any certification or authorization to prescribe or administer medication. SMI Adviser is not intended to be a substitute for independent professional medical advice, diagnosis or treatment. SMI Adviser does not endorse or recommend any pharmaceutical or other treatment as an appropriate course for any particular patient or condition. The advice of a physician or other qualified health provider should be obtained for a treatment recommendation or to answer any questions regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on SMI Adviser. SMI Adviser is provided as-is and is not guaranteed to be correct, complete or current. APA makes no warranty, expressed or implied, about the accuracy, applicability, fitness, completeness or reliability of the information contained within SMI Adviser. APA assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of SMI Adviser or for any errors or omissions. The limitations applicable to the SMI Adviser consultation feature are set forth at: https://smiadviser.org/limitations-of-consultation
About SMI Adviser
The company that develops SMI Adviser is American Psychiatric Association. The latest version released by its developer is 1.3.1.
To install SMI Adviser on your Android device, just click the green Continue To App button above to start the installation process. The app is listed on our website since 2024-05-01 and was downloaded 0 times. We have already checked if the download link is safe, however for your own protection we recommend that you scan the downloaded app with your antivirus. Your antivirus may detect the SMI Adviser as malware as malware if the download link to org.smiadviser is broken.
How to install SMI Adviser on your Android device:
- Click on the Continue To App button on our website. This will redirect you to Google Play.
- Once the SMI Adviser is shown in the Google Play listing of your Android device, you can start its download and installation. Tap on the Install button located below the search bar and to the right of the app icon.
- A pop-up window with the permissions required by SMI Adviser will be shown. Click on Accept to continue the process.
- SMI Adviser will be downloaded onto your device, displaying a progress. Once the download completes, the installation will start and you'll get a notification after the installation is finished.
Program Details
System requirements
Download information
Pricing
Version History
version 1.3.1
posted on 2024-05-01
- Knowledge Base updates
version 1.3.0
posted on 2024-03-26
- New interactive tool for clinicians: App Evaluation Screener
version 1.2.6
posted on 2023-12-21
- Updates to LAI dose conversion tool
version 1.2.5.5
posted on 2023-08-16
- Updated conversion information for Risperidone in LAI Conversion Tool
version 1.2.5.4
posted on 2023-08-09
- New tool to help predict clozapine level and dose needed to achieve that level based on smoking status, sex, weight, and age
version 1.2.5.3
posted on 2023-06-13
- New tool to convert oral to long-acting injectable antipsychotics
version 1.2.5.2
posted on 2023-05-09
- Improved Education Catalog
version 1.2.5.1
posted on 2022-11-30
- Bug Fixes
version 1.2.4
posted on 2022-04-12
- Added new Questionnaire: Alcohol Use Disorders Identification Test-Concise (AUDIT-C)
- Added PDF sharing functionality for all Questionnaires
version 1.2.3
posted on 2021-12-03
- Minor Bug Fixes



